New approach aims to tame blood cancers with fewer side effects
NCT ID NCT05184842
Summary
This study is testing a new, lower-dose weekly schedule of two approved drugs (decitabine and venetoclax) for people with certain blood cancers like AML and MDS. The goal is to see if this gentler approach can control the cancer while causing fewer severe side effects and treatment interruptions than the standard dosing. Researchers will enroll up to 91 adults who have these conditions and may not tolerate the standard treatment well.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-••••
-
University of California Davis Health (UC Davis Health)
RECRUITINGSacramento, California, 95817, United States
-
White Plains Hospital
RECRUITINGWhite Plains, New York, 10601, United States
Conditions
Explore the condition pages connected to this study.